Advice
Following a full submission.
Insulin detemir is accepted for restricted use within NHS Scotland for the treatment of diabetes mellitus.
Insulin detemir is an acceptable basal insulin for patients with diabetes mellitus. Its use should be targeted on patients attempting to achieve better hypoglycaemic control as there may be some benefit related to a reduced intra-individual variation in glycaemic profile for insulin detemir compared with established insulins. It appears to be cost-effective from the base-case of economic modelling, but this is limited by the degree of extrapolation involved and the associated width of the confidence intervals.
Download detailed advice27KB (PDF)
Medicine details
- Medicine name:
- Insulin detemir (Levemir®)
- SMC ID:
- 110/04
- Indication:
- Diabetes mellitus
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 August 2004